Ozempic and Wegovy both contain semaglutide — but they are not the same drug and are not interchangeable. Ozempic is approved for type 2 diabetes at up to 2mg weekly (7–10% weight loss). Wegovy is approved for obesity at up to 2.4mg weekly (15% weight loss) — and the new Wegovy HD at 7.2mg (approved March 2026) pushes that to 20%+. This complete 2026 comparison covers every difference: FDA indications, dose titration charts, weight loss outcomes, new oral forms.

Metformin is the world's most prescribed diabetes drug — and in 2026, it is also the world's most studied anti-aging medicine. An NIH-funded clinical trial called TAME is testing whether Metformin 1,500mg daily can delay the onset of cancer, heart disease, and dementia simultaneously in 3,000 non-diabetic Americans.

Ozempic (semaglutide) is America's most searched drug — and in 2026 the landscape has changed dramatically. The 3-year shortage is officially over. Oral semaglutide tablets are now FDA-approved. Wegovy HD (7.2mg) has launched. And compounded semaglutide has been shut down by the FDA.